Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Steenholdt

Letter: Can Addition of an Immunomodulator Really Reverse Antibody Formation and Loss of Response in Patients Treated With Adalimumab?

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Related publications

Letter: Can Addition of an Immunomodulator Really Reverse Antibody Formation and Loss of Response in Patients Treated With Adalimumab? Authors’ Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Letter: Double-Dose Intensification - A Quick Way to Reverse Antibody Formation and Loss of Response in Patients Treated With Adalimumab

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Letter: Double-Dose Intensification-A Quick Way to Reverse Antibody Formation and Loss of Response in Patients Treated With Adalimumab. Authors Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Suppression of Anti-Drug Antibodies to Infliximab or Adalimumab With the Addition of an Immunomodulator in Patients With Inflammatory Bowel Disease

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Letter: The Addition of an Immunosuppressant in Patients With Unsatisfactory Response to Vedolizumab

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Letter: The Addition of an Immunosuppressant in Patients With Unsatisfactory Response to Vedolizumab-Authors' Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Letter: Addition of Methotrexate Neither Restores Clinical Response Nor Improves the Pharmacokinetic Profile of Vedolizumab-Treated Patients

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Label-Free Quantification of Anti-TNF-Α in Patients Treated With Adalimumab Using an Optical Biosensor

Instrumentation

Information Systems

Electronic Engineering

Analytical Chemistry

Molecular Physics,

English

Dose Escalation Among Ulcerative Colitis Patients Treated With Adalimumab in Sweden

Value in Health

Occupational Health

English